Generalized anxiety disorder

Generalized anxiety disorder (GAD) is a condition marked by persistent, excessive worry that feels out of control and often lacks a clear basis. This worry typically gets in the way of day-to-day life. People with GAD may fixate on routine concerns like health, money, death, family, relationships, or work, though not everyone does. Common symptoms include a constant state of worry, feeling keyed up or on edge, trouble sleeping, fatigue, irritability, sweating, and trembling. For a formal diagnosis, these symptoms must be steady and last for at least six months. Globally, about 2 to 6 percent of adults are affected. The disorder often starts in adolescence or early adulthood, is more common in women, and tends to come and go over a person’s lifetime.

Both genetic and environmental factors play a role. A hereditary component, linked to brain structure and how neurotransmitters function, interacts with life stressors such as parenting style and abusive relationships. There is also growing evidence that heavy use of digital media may contribute to increased anxiety. On a brain level, GAD involves overactivity in the amygdala and prefrontal cortex, reflecting an overly sensitive threat-response system. The disorder was first defined as a separate diagnosis in 1980, and its diagnostic criteria have changed over time, which has made research and treatment development more complicated.

People with GAD often have other conditions, including other psychiatric disorders, substance use disorder, or obesity. They may also have a history of trauma or a family history of GAD. Clinicians use screening tools like the GAD-7 and GAD-2 to identify who might have GAD and needs a full evaluation. These tools also help gauge how severe the symptoms are.

Treatment typically involves psychotherapy, medication, or both, with combined therapy generally seen as the most effective approach. The first-line psychological treatment is cognitive behavioral therapy (CBT), while first-line medications include selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs). In more severe cases where other options have failed, benzodiazepines (BZs) may be used, but they are habit-forming and often abused. Pregabalin is another effective treatment with a low risk of dependence. Researchers have also studied complementary and alternative medicines, exercise, therapeutic massage, and other interventions. Brain stimulation, LSD, and other novel therapies are still being investigated.

The causes section covers genetics, family, and environment. The genetic basis of GAD is still being explored. While it is known to run in families, no single gene has been definitively linked to it. Several genetic regions of interest have been identified, and genetic factors influence risk, brain changes related to anxiety, and how well someone responds to treatment. Family and twin studies show that first-degree relatives are more likely to have GAD than unrelated people. One 2025 study in *Psychological Medicine* found that genetic factors accounted for symptom stability, while environmental factors drove changes in symptoms. Heritability at single assessments was 39 to 46 percent, but when stability across ages 23 to 26 was modeled, it rose to about 60 percent, suggesting genetics play a stronger role in persistent GAD. Another 2025 review in *Psychiatric Clinics of North America* reported that overall genetic contribution to anxiety disorders, including GAD, ranges from 30 to 50 percent, with SNP-based heritability between 5 and 30 percent. This indicates common variants explain only part of the risk, while rare variants and epigenetic processes are also important. Twin studies also suggest a genetic link between GAD and major depressive disorder, which may help explain why about 60 percent of people with GAD also have depression.

Environmental factors include parenting styles, with evidence that parents modeling anxious behaviors may increase risk. People with GAD also tend to experience more minor stressful events, and these cumulative stressors may be significant. Social context matters too: interpersonal difficulties and partner abuse in women are strongly linked to anxiety symptoms. Strained or abusive relationships appear to be one environmental factor in the development of GAD.

Genetic studies have looked at genes involved in brain structures like the amygdala and those affecting neurotransmitter systems and receptor activity. Some genes have been tied to treatment response. For example, the Asp54Gly polymorphism of the ADCYAP1 gene has been linked to remission after venlafaxine treatment. Variants in the serotonin receptor 2A gene (HTR2A), particularly the rs7997012 SNP G allele, have been associated with reduced anxiety after venlafaxine therapy. Interactions between the serotonin transporter gene SLC6A4 and HTR2A polymorphisms also predict response to venlafaxine.

The pathophysiology of GAD is an active area of research, often involving the intersection of these genetic and environmental factors.